Journal of Neural Transmission

, Volume 109, Issue 2, pp 175–179

3-OMD and homocysteine plasma levels in parkinsonian patients

  • Th. Müller
  • D. Woitalla
  • B. Fowler
  • W. Kuhn

DOI: 10.1007/s007020200013

Cite this article as:
Müller, T., Woitalla, D., Fowler, B. et al. J Neural Transm (2002) 109: 175. doi:10.1007/s007020200013

Summary.

One main metabolizing pathway of levodopa is O-methylation to 3-O-methyldopa (3-OMD) by catechol-O-methyltransferase (COMT). Since COMT requires Mg2+ and S-adenosylmethionine as methyl donor for this transmethylating process, COMT converts S-adenosylmethionine to S-adenosylhomocysteine and subsequent homocysteine. Objective of this study was to demonstrate relations between plasma levodopa, 3-OMD and total homocysteine in treated parkinsonian subjects. We measured homocysteine, levodopa and 3-OMD by HPLC. We compared plasma homocysteine in two groups of treated parkinsonian subjects subdivided according to their 3-OMD level. Homocysteine was significantly (p = 0.002) elevated in the group with higher 3-OMD concentrations and positively (r = 0.52, p = 0.0006) correlated to 3-OMD. Homocysteine induces vascular disease. Previous studies showed an increase of ischaemic heart- and cerebrovascular disease in treated parkinsonian patients.

Keywords: Homocysteine3-OMDParkinson's disease.

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • Th. Müller
    • 1
  • D. Woitalla
    • 1
  • B. Fowler
    • 2
  • W. Kuhn
    • 1
  1. 1.Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Federal Republic of GermanyDE
  2. 2.University Children's Hospital, Basel, SwitzerlandCH